127 related articles for article (PubMed ID: 32988910)
1. Clinical Significance of Glioma-associated Oncogene 1 Expression in Patients With Locally Advanced Gastric Cancer Administered Adjuvant Chemotherapy With S-1 After Curative Surgery.
Hashimoto I; Oue N; Kimura Y; Hiroshima Y; Hara K; Maezawa Y; Kano K; Fujikawa H; Aoyama T; Numata M; Yamada T; Tamagawa H; Yamamoto N; Ogata T; Shiozawa M; Morinaga S; Rino Y; Yasui W; Masuda M; Miyagi Y; Oshima T
Anticancer Res; 2020 Oct; 40(10):5815-5821. PubMed ID: 32988910
[TBL] [Abstract][Full Text] [Related]
2. Clinical Significance of
Katayama Y; Oshima T; Sakamaki K; Aoyama T; Sato T; Masudo K; Shiozawa M; Yoshikawa T; Rino Y; Imada T; Masuda M
In Vivo; 2017; 31(4):565-571. PubMed ID: 28652421
[TBL] [Abstract][Full Text] [Related]
3. High gamma-glutamyl hydrolase and low folylpolyglutamate synthetase expression as prognostic biomarkers in patients with locally advanced gastric cancer who were administrated postoperative adjuvant chemotherapy with S-1.
Maezawa Y; Sakamaki K; Oue N; Kimura Y; Hashimoto I; Hara K; Kano K; Aoyama T; Hiroshima Y; Yamada T; Yamamoto N; Ogata T; Ito H; Cho H; Shiozawa M; Yoshikawa T; Morinaga S; Rino Y; Yasui W; Masuda M; Miyagi Y; Oshima T
J Cancer Res Clin Oncol; 2020 Jan; 146(1):75-86. PubMed ID: 31754833
[TBL] [Abstract][Full Text] [Related]
4. Clinical Significance of Tensin 4 Gene Expression in Patients with Gastric Cancer.
Sawazaki S; Oshima T; Sakamaki K; Aoyama T; Sato T; Shiozawa M; Yoshikawa T; Rino Y; Imada T; Masuda M
In Vivo; 2017; 31(6):1065-1071. PubMed ID: 29102927
[TBL] [Abstract][Full Text] [Related]
5. Clinical Significance of
Hatori S; Sakamaki K; Yokohori T; Kimura Y; Hiroshima Y; Hashimoto I; Komori K; Watanabe H; Kano K; Fujikawa H; Aoyama T; Numata M; Yamada T; Tamagawa H; Yamamoto N; Ogata T; Shizawa M; Yukawa N; Morinaga S; Rino Y; Masuda M; Saeki H; Miyagi Y; Oshima T
Anticancer Res; 2021 Jul; 41(7):3583-3588. PubMed ID: 34230154
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of IGF1R gene expression in patients with Stage II/III gastric cancer who receive curative surgery and adjuvant chemotherapy with S-1.
Numata K; Oshima T; Sakamaki K; Yoshihara K; Aoyama T; Hayashi T; Yamada T; Sato T; Cho H; Shiozawa M; Yoshikawa T; Rino Y; Kunisaki C; Akaike M; Imada T; Masuda M
J Cancer Res Clin Oncol; 2016 Feb; 142(2):415-22. PubMed ID: 26337161
[TBL] [Abstract][Full Text] [Related]
7. Impact of insulin-like growth factor-1 receptor and amphiregulin expression on survival in patients with stage II/III gastric cancer enrolled in the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer.
Ichikawa W; Terashima M; Ochiai A; Kitada K; Kurahashi I; Sakuramoto S; Katai H; Sano T; Imamura H; Sasako M
Gastric Cancer; 2017 Mar; 20(2):263-273. PubMed ID: 26884344
[TBL] [Abstract][Full Text] [Related]
8. Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial.
Ito S; Ohashi Y; Sasako M
BMC Cancer; 2018 Apr; 18(1):449. PubMed ID: 29678146
[TBL] [Abstract][Full Text] [Related]
9. An increase in the neutrophil-to-lymphocyte ratio during adjuvant chemotherapy indicates a poor prognosis in patients with stage II or III gastric cancer.
Mori M; Shuto K; Kosugi C; Narushima K; Hayashi H; Matsubara H; Koda K
BMC Cancer; 2018 Dec; 18(1):1261. PubMed ID: 30558575
[TBL] [Abstract][Full Text] [Related]
10. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.
Tsuburaya A; Yoshida K; Kobayashi M; Yoshino S; Takahashi M; Takiguchi N; Tanabe K; Takahashi N; Imamura H; Tatsumoto N; Hara A; Nishikawa K; Fukushima R; Nozaki I; Kojima H; Miyashita Y; Oba K; Buyse M; Morita S; Sakamoto J
Lancet Oncol; 2014 Jul; 15(8):886-93. PubMed ID: 24954805
[TBL] [Abstract][Full Text] [Related]
11. Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer.
Jeong JH; Park SR; Ahn Y; Ryu MH; Ryoo BY; Kong SY; Yook JH; Yoo MW; Kim BS; Kim BS; Kang YK
Gastric Cancer; 2017 Jan; 20(1):146-155. PubMed ID: 26715117
[TBL] [Abstract][Full Text] [Related]
12. GLI1 overexpression promotes gastric cancer cell proliferation and migration and induces drug resistance by combining with the AKT-mTOR pathway.
Yao Y; Zhou D; Shi D; Zhang H; Zhan S; Shao X; Sun K; Sun L; Wu G; Tian K; Zhu X; He S
Biomed Pharmacother; 2019 Mar; 111():993-1004. PubMed ID: 30841479
[TBL] [Abstract][Full Text] [Related]
13. Impact of intratumoral expression levels of fluoropyrimidine-metabolizing enzymes on treatment outcomes of adjuvant S-1 therapy in gastric cancer.
Kim JY; Shin E; Kim JW; Lee HS; Lee DW; Kim SH; Lee JO; Kim YJ; Kim JH; Bang SM; Ahn SH; Park DJ; Lee JS; Lee JS; Kim HH; Lee KW
PLoS One; 2015; 10(3):e0120324. PubMed ID: 25793299
[TBL] [Abstract][Full Text] [Related]
14. GLI1-mediated regulation of side population is responsible for drug resistance in gastric cancer.
Yu B; Gu D; Zhang X; Li J; Liu B; Xie J
Oncotarget; 2017 Apr; 8(16):27412-27427. PubMed ID: 28404967
[TBL] [Abstract][Full Text] [Related]
15. Time to initiation or duration of S-1 adjuvant chemotherapy; which really impacts on survival in stage II and III gastric cancer?
Fujitani K; Kurokawa Y; Takeno A; Endoh S; Ohmori T; Fujita J; Yamasaki M; Takiguchi S; Mori M; Doki Y;
Gastric Cancer; 2018 May; 21(3):446-452. PubMed ID: 28965205
[TBL] [Abstract][Full Text] [Related]
16. Bioinformatic Analysis of GLI1 and Related Signaling Pathways in Chemosensitivity of Gastric Cancer.
Yu T; Jia W; An Q; Cao X; Xiao G
Med Sci Monit; 2018 Mar; 24():1847-1855. PubMed ID: 29596399
[TBL] [Abstract][Full Text] [Related]
17. Chemo-resistant Gastric Cancer Associated Gene Expression Signature: Bioinformatics Analysis Based on Gene Expression Omnibus.
Liu JB; Jian T; Yue C; Chen D; Chen W; Bao TT; Liu HX; Cao Y; Li WB; Yang Z; Hoffman RM; Yu C
Anticancer Res; 2019 Apr; 39(4):1689-1698. PubMed ID: 30952707
[TBL] [Abstract][Full Text] [Related]
18. Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy.
Cho JH; Lim JY; Cho JY
PLoS One; 2017; 12(10):e0186362. PubMed ID: 29040299
[TBL] [Abstract][Full Text] [Related]
19. Nuclear Gli1 expression is associated with pathological complete response and event-free survival in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant therapy.
Liu S; Duan X; Xu L; Ye J; Cheng Y; Liu Q; Zhang H; Zhang S; Zhu S; Li T; Liu Y
Tumour Biol; 2016 Apr; 37(4):4873-81. PubMed ID: 26526577
[TBL] [Abstract][Full Text] [Related]
20. Prognostic analysis of stage III gastric cancer after curative surgery according to the newest TNM classification.
Wei J; Yao T; Wang Y; Li L; Pan C; Zhang N
Clin Transl Oncol; 2019 Feb; 21(2):232-238. PubMed ID: 29968135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
